{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:33:28Z","timestamp":1791308008451,"version":"4.3.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate whether daily enoxaparin, added to low-dose aspirin, started before 14 weeks of gestation reduces placenta-mediated complications in pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>In this open-label multicenter randomized trial, we enrolled consenting pregnant women with previous severe preeclampsia diagnosed before 34 weeks of gestation, gestational age at randomization of 7\u201313 weeks, singleton pregnancy, and no plan for anticoagulation. Eligible patients were randomly assigned to a one-to-one ratio to receive daily either 4,000 international units enoxaparin plus 100 mg aspirin or 100 mg aspirin alone. Randomization was done by a web-based randomization system. The primary composite outcome comprised maternal death, perinatal death, preeclampsia, small for gestational age (less than the 10th percentile), and placental abruption. A sample size of 232 women equally divided into two groups was needed to detect a significant reduction in primary outcome from 55% in the aspirin group to 36.7% in the enoxaparin-aspirin group (\u03b1: 0.05, \u03b2: 0.8, two-sided).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Between November 14, 2009, and February 21, 2015, 257 participants were enrolled. Baseline demographic and clinical factors were similar between groups. Eight women were excluded after randomization (six in the enoxaparin\u2013aspirin group and two in the aspirin group), leaving 124 participants assigned to enoxaparin\u2013aspirin and 125 to aspirin. Five participants were lost to follow-up (two in the enoxaparin\u2013aspirin group and three in the aspirin group). There was no significant difference between the groups in the primary outcome: enoxaparin\u2013aspirin 42 of 122 (34.4%) compared with aspirin alone 50 of 122 (41%) (relative risk 0.84, 95% confidence interval 0.61\u20131.16, <jats:italic toggle=\"yes\">P<\/jats:italic>=.29). The occurrence of complications did not differ between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Antepartum prophylactic enoxaparin does not significantly reduce placenta-mediated complications in women receiving low-dose aspirin for previous severe preeclampsia diagnosed before 34 weeks of gestation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov, NCT00986765.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000001673","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T12:15:01Z","timestamp":1476274501000},"page":"1053-1063","source":"Crossref","is-referenced-by-count":90,"title":["Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications"],"prefix":"10.1097","volume":"128","author":[{"given":"Bassam","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvon","family":"Chitrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Houfflin-Debarge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Chauleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Tsatsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Benachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Bretelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Gris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bastuji-Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Heparin-Preeclampsia (HEPEPE) Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mob.2000.107928","article-title":"Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy","volume":"183","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199803123381101","article-title":"Low-dose aspirin to prevent preeclampsia in women at high risk","volume":"338","author":"Caritis","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1067\/mob.2002.120280","article-title":"Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparous","volume":"186","author":"Hnat","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00006250-200212000-00037","article-title":"Chronic hypertension in pregnancy","volume":"100","author":"Sibai","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0002-9378(00)70350-4","article-title":"Hypertensive disorders in twin versus singleton gestations","volume":"182","author":"Sibai","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ajog.2004.03.050","article-title":"Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation","volume":"190","author":"Haddad","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/0002-9378(86)90336-4","article-title":"Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis","volume":"155","author":"Sibai","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ajog.2006.06.044","article-title":"Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia","volume":"195","author":"van Rijn","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.ajog.2011.02.014","article-title":"Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study","volume":"204","author":"Bramham","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1471-0528.2010.02842.x","article-title":"Recurrence risk and prediction of a delivery under 34 weeks of gestation after a history of a severe hypertensive disorder","volume":"118","author":"Langenveld","year":"2011","journal-title":"BJOG"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2013-01-478958","article-title":"Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications","volume":"123","author":"Rodger","year":"2014","journal-title":"Blood"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","article-title":"Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial","volume":"384","author":"Rodger","year":"2014","journal-title":"Lancet"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00431-005-0045-4","article-title":"Identification of newborns with Fetal Growth Restriction (FGR) in weight and\/or length based on constitutional growth potential","volume":"165","author":"Mamelle","year":"2006","journal-title":"Eur J Pediatr"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2288-13-58","article-title":"Assessing potential sources of clustering in individually randomized trials","volume":"13","author":"Kahan","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"R15-20230711","first-page":"1122","article-title":"Hypertension in pregnancy. American College of Obstetricians and Gynecologists","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jri.2013.09.001","article-title":"Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors","volume":"101\u2013102","author":"Staff","year":"2014","journal-title":"J Reprod Immunol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/HYPERTENSIONAHA.115.05770","article-title":"Current theories on the prevention of severe preeclampsia with low-molecular weight heparin","volume":"66","author":"McLaughlin","year":"2015","journal-title":"Hypertension"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1055\/s-0037-1613894","article-title":"Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin","volume":"83","author":"Brenner","year":"2000","journal-title":"Thromb Haemost"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0015-0282(02)03222-3","article-title":"Preventing adverse obstetric outcomes in women with genetic thrombophilia","volume":"78","author":"Grandone","year":"2002","journal-title":"Fertil Steril"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10641950109152640","article-title":"Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias","volume":"20","author":"Kupferminc","year":"2001","journal-title":"Hypertens Pregnancy"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-05-0340","article-title":"Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial","volume":"106","author":"Gris","year":"2011","journal-title":"Thromb Haemost"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/01.HYP.0000149950.05182.a3","article-title":"Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women","volume":"45","author":"Mello","year":"2005","journal-title":"Hypertension"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1538-7836.2008.03230.x","article-title":"Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial","volume":"7","author":"Rey","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1160\/TH10-03-0167","article-title":"Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial","volume":"104","author":"Gris","year":"2010","journal-title":"Thromb Haemost"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood-2011-11-391383","article-title":"Heparin in pregnant women with previous placenta mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial","volume":"119","author":"Martinelli","year":"2012","journal-title":"Blood"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1538-7836.2011.04553.x","article-title":"Low-molecular-weight heparin added to aspirin in the prevention ofrecurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT","volume":"10","author":"deVries","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201611000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T19:29:40Z","timestamp":1689103780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201611000-00017"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001673","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}